Objective-To examine use of thrombolytic drugs for myocardial infarction and use of contraindications to treatment in the United Kingdom. Design-Observational study, based on a continuing audit. Early and accurate recognition of the electrocardiographic changes of myocardial infarction is a prerequisite for the effective use of thrombolytic treatment. It is accepted that benefit extends to patients who show typical ST segment elevation or new left bundle branch block on the ECG, changes that are associated with thrombotic occlusion of a major epicardial artery.1-3 Benefit in infarction where there are not typical ST segment changes is not proven.
Patients-30 029 patients admitted between November 1992 and June 1995 with suspected myocardial infarction. Results-Of 13 628 patients with a final diagnosis of definite myocardial infarction 10 316 (75.7%) were considered eligible for thrombolytic treatment on the basis of typical cardiographic changes or new left bundle branch block. Of these, 8139 (59-7%) were diagnosed at admission to hospital and 6991 (85.90/o) were administered thrombolytic drugs; 14'1% were considered too late for treatment or had a clinical contraindication. In 2177 patients (16% of 13 628) thrombolytic treatment was given in the absence of contraindications and after the diagnosis of infarction had been confirmed by further electrocardiographic evidence. A further 591 (4.3%) with a final diagnosis of definite infarction without typical cardiographic changes also received thrombolytic treatment as did 1018 patients without a final diagnosis of definite infarction. In total, 9459 of 13 628 patients (71-6%) received thrombolytic treatment. The range of use of treatment between hospitals for a final diagnosis of infarction was 49-1-85*4%. This variation reflected differences in the frequency with which a diagnosis of definite myocardial infarction was made at admission, and the subsequent use of clinical contraindications to thrombolytic treatment.
Conclusions-75-7% of patients with a final diagnosis of definite myocardial infarction were eligible for thrombolytic treatment on the basis of cardiographic changes. Differences between hospitals in the frequency with which a diagnosis of infarction was made on admission, and differences in subsequent use of thrombolytic drugs, results in wide variation in treatment rates. Differences in use of thrombolytic treatment mainly reflect different thresholds for the use of clinical contraindications relating to haemorrhagic risk. (Heart 1997; 78:28-33) Keywords: thrombolytic treatment; myocardial infarction; audit Early and accurate recognition of the electrocardiographic changes of myocardial infarction is a prerequisite for the effective use of thrombolytic treatment. It is accepted that benefit extends to patients who show typical ST segment elevation or new left bundle branch block on the ECG, changes that are associated with thrombotic occlusion of a major epicardial artery.1-3 Benefit in infarction where there are not typical ST segment changes is not proven.
In theory the ideal figure for the use of thrombolytic treatment is the sum of patients eligible on ECG criteria minus those who have clear contraindications to treatment, either because of a perceived bleeding risk or because the delay after onset of symptoms is excessive. In practice this figure is not easily determined because neither cardiographic appearances nor contraindications are categorical variables and are subject to individual interpretation. In three recent large studies having similar enrolment criteria the proportion of patients with ECG ST segment elevation and who were thus eligible for thrombolytic treatment differed widely. In ISIS-2 66% of patients had ST elevation, The contraindications to the use of thrombolytic treatment that reflect bleeding risk evolved over time as experience of this treatment increased. They may have become less stringent; in the GISSI-1 study (1984-85) 13-1% were considered to have a relative or absolute contraindication to thrombolysis1 while in GISSI-2 (1988-89) The diagnostic criteria used at admission were: Definite infarction-A single episode of chest pain with the following ECG changes: ST elevation > 1 mm in two limb leads, and/or ST elevation > 2 mm in two contiguous chest leads, and/or new pathological Q waves. For the final diagnosis cardiac enzymes had to be greater than twice the upper limit of normal.
Probable infarction-A single episode of chest pain with an abnormal but non-diagnostic cardiograph, and an enzyme release of less than twice the upper limit of normal. Unstable angina-The development of spontaneous episodes of ischaemic pain or an increase in the frequency of ischaemic pain arising at rest or on minimal exertion. The cardiograph could be normal or abnormal and appearances could fluctuate but were not diagnostic of infarction. Ischaemic heart disease-A single episode of chest pain, thought to be cardiac in origin, in a patient with a previous history of ischaemic heart disease. Chest pain of uncertain cause-A single episode of chest pain, thought to be cardiac in origin, in a patient without a previous history of ischaemic heart disease.
A preprogrammed Psion organiser (Series II) was used for data collection. Data were collected prospectively during the course of the admission. It was not possible to identify an individual patient once the data had been entered. Data analysis was then performed centrally.
All treatment decisions were based on local protocols and the decision to use thrombolytic treatment was that of the junior staff of the collaborating hospitals.
DATA ANALYSIS
Proportions and their differences are expressed as percentages followed by 99% confidence intervals (CI) for the difference. For patients with an admission diagnosis of definite infarction "too late" and "clinical contraindications" were used less frequently as use of thrombolytic treatment increased (table  4) . For a final diagnosis of definite infarction a similar trend was observed for these contraindications and a more extreme trend in the use of the contraindications clinical uncertainty and non-diagnostic ECG was observed, these contraindications being used almost three times more frequently in the group of hospitals with the lowest use of thrombolytic treatment than the highest.
Results

Discussion
Data were recorded between November 1992 and June 1995 from 39 district general hospitals with an average input of 349 patients (range 97-836) with a final diagnosis of myocardial infarction. These data come from hospitals with a wide geographical spread and might be considered typical of recent UK practice.
ELIGIBILITY FOR THROMBOLYTIC TREATMENT
There were 59 7% patients with a final diagnosis of myocardial infarction who had this diagnosis made at admission on the basis of a suggestive history confirmed by cardiographic changes. This diagnosis carried a positive predictive value for confirmed myocardial infarction of 96-7%. When these data were recalculated on the criteria used by French'2 (using patients with a final diagnosis of definite or probable infarction and excluding patients who were too late) 54-5% of patients were eligible compared with 53-3% in that study.
It is recognised that typical ECG changes of infarction may be transient or slow to evolve,'3 so that a proportion of patients will only become eligible for thrombolytic treatment at some point after admission, emphasising the importance of frequent review of the cardiograph to ensure appropriate treatment. In this study 2177 of 13 628 patients (16%) developed qualifying ST segment changes or left bundle branch block after admission and received thrombolysis. This figure is likely to represent the majority of remaining eligible patients although this cannot be stated with certainty as the cardiographic appearances of patients not having thrombolytic treatment were not recorded in this study. Thus, 75-7% patients were eligible for treatment with a proviso that this may be lower than the true figure if any other patients who developed qualifying ST segment shifts after admission were not recognised. This figure lies within the range proposed by Ketley and Woods.8 INELIGIBLE PATIENTS In this study 3312 of 13 628 patients (24-3%) with a final diagnosis of infarction did not have typical ECG changes (or did not have them recognised). This figure is lower than the 32-3% recorded by French from New Zealand'2 and may indicate a lower threshold for the use of thrombolytic treatment for borderline cardiographic appearances in the UK. Of these patients, 591 received thrombolytic treatment.
The group of patients without typical ST segment changes represent a spectrum. This includes patients who have small infarctions unlikely to benefit from thrombolytic treatment, and in whom the risk:benefit ratio may be adverse; patients with extensive ST segment depression where severe three vessel disease is found postmortem and where evidence of benefit is uncertain despite being a high risk group;' 4 and patients with previous infarction who do not always present with typical changes but who have a high mortality and may benefit from thrombolytic treatment.'4 It seems biologically implausible that the benefit of thrombolytic treatment should be entirely limited to patients having ST segment elevation on the ECG. Uncertainty concerning benefit for those having infarction with atypical cardiographic changes is partly because they are a heterogenous group in terms of risk and partly because, at least for patients with extensive ST segment depression, the available evidence neither confirms nor excludes the possibility of benefit.'4 The overall picture is far from clear, and in some areas it is paradoxical. Although patients with previous infarction appear to benefit from treatment'4 they frequently present with ST segment depression, a group presently thought not to show evidence of benefit. '4 15 Even patients admitted with suspected infarction who have minor cardiographic changes have significant early mortality. In ISIS-2 patients randomised to a placebo arm, not all of whom would have had infarction, and who had a cardiographic classification of other abnormality had a 35 day mortality of 5-4-6-3%.4 No trial has explicitly examined the effect of thrombolytic treatment for patients with definite infarction and atypical ECG changes. Lack of evidence of benefit is not good evidence of lack of benefit. The possibility remains that some patients with infarction and atypical ECG changes may benefit from thrombolytic treatment. In present UK practice it would appear that some patients from this uncertain group are presently receiving the benefit of the doubt. Doubt will remain until a definitive study in this group of patients is performed.
USE OF CONTRAINDICATIONS
The LATE study showed that significant benefit from treatment did not extend beyond 12 hours after onset of symptoms. '6 Collaborators in this audit adopted local protocols; data on file suggests that in practice the time window accepted for use of thrombolytic treatment is greater than 12 hours in some hospitals. Older patients and women (who present at an older age) were more often too late for treatment. This may reflect the atypical nature of symptoms in the elderly,'7 and in women,'8 and the greater use of general practitioner contact by both groups as a means of admission to hospital.
The use of clinical contraindications in 6 1% of patients with an admission diagnosis of infarction is similar to recent published work from New Zealand (6 8%)." The "other" clinical contraindications used in this study included a number of contraindications which appear overcautious or inappropriate, such as the need for pacing, or when there was cardiogenic shock. There was a trend to greater use of clinical and other contraindications by the hospitals who used the least thrombolytic treatment, which may reflect excessive caution. When patients had a delayed diagnosis the dominant reasons for not using thrombolytic treatment were clinical uncertainty or a non-diagnostic cardiograph. Both of these contraindications involve subjective judgment, with use determined by the clinical acumen of the clinician, or by the strictness of interpretation of the ECG criteria.
THE INFLUENCE OF PREVIOUS INFARCTION
About one quarter of patients with a diagnosis of infarction have had previous infarction. They have a high mortality rate and may benefit from thrombolytic treatment.'4 Previous infarction makes ECG recognition of further infarction more difficult." The lower use of thrombolytic treatment for patients with previous infarction found in this study supports this finding. Only 46-6% of patients with previous infarction had the diagnosis recognised at admission. As a result of this diagnostic uncertainty patients with previous infarction received thrombolytic treatment less often than first infarctions (64-6% v 73.9%).
Patients with previous infarction admitted to hospitals with a low use of thrombolytic treatment were also less likely to have previous infarction recognised and treated with thrombolytic drugs than patients admitted to the average or high use groups (39 7% v 500% and 48 6%). It is clear that patients with previous infarction are at a disadvantage. The frequency with which the diagnosis is missed at admission may represent a lack of clinical awareness, as in the low use group, but might also be improved by the use of rapid assay enzyme analysis.
DIFFERENCES IN PRACTICE BETWEEN HOSPITALS IN THE LOW, AVERAGE, AND HIGH USE GROUPS
Increasing use of the contraindications "too late" and "clinical contraindications" accounted for the difference in the use of thrombolytic treatment for patients with an admission diagnosis of infarction (table 4). These differences are more marked for a final diagnosis of infarction. There was a threefold difference in the use of the contraindications "clinical uncertainty" and "non-diagnostic ECG" between the low and high use groups, which was the main but not only factor in the observed differences. It is probable that these differences are determined by local policy and attitudes to treatment, rather than intrinsic differences between groups.
Making an immediate diagnosis of infarction is the crucial first step in treating infarction with thrombolytic drugs. This 
